Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β-tubulin (Asp26Glu) and less stable microtubules

Molecular Cancer Therapeutics

Volumn 5, Issue 2, 2006, Pages 270-278

  Hari, Malathi ^a   Loganzo, Frank ^a   Annable, Tami ^a   Tan, Xingzhi ^a   Musto, Sylvia ^a   Morilla, Daniel B ^a   Nettles, James H ^b,c   Snyder, James P ^b   Greenberger, Lee M ^a,d  

^a Oncology Research   (United States)

^b EMORY UNIVERSITY   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; BETA TUBULIN; BISANTRENE; DOCETAXEL; DOLASTATIN 10; DOXORUBICIN; EPOTHILONE B; GLUTAMIC ACID; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; HYDROGEN; MAC 321; MITOXANTRONE; PACLITAXEL; TALTOBULIN; TAXANE DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG; VINBLASTINE; ZINC;

ACETYLATION; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; CRYSTALLOGRAPHY; DRUG ACCUMULATION; DRUG BINDING; DRUG EXPOSURE; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG STRUCTURE; EPIDERMOID TUMOR; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYDROGEN BOND; MICROTUBULE; MOUSE; NONHUMAN; NUDE MOUSE; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN POLYMERIZATION; PROTEIN STRUCTURE; TISSUE CULTURE; TUMOR VOLUME;

AMINO ACID SUBSTITUTION; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ASPARTIC ACID; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; GLUTAMIC ACID; HUMANS; MICE; MICE, NUDE; MICROTUBULES; P-GLYCOPROTEIN; PACLITAXEL; POINT MUTATION; PROTEIN CONFORMATION; TAXOIDS; TUBULIN; VERAPAMIL;

EID: 33644977169     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0190     Document Type: Article

References (45)

1. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-7.
2. Rowinsky EK, Tolcher AW. Antimicrotubule agents. In: Devita Jr. VT, Hellman S, Rosenberg SA, editors. Cancer principles and practice, 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 431-52.
3. Sampath D, Discafani CM, Loganzo F, et al. MAC-321, A novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo. Mol Cancer Thera 2003;2:873-994.
4. Cabral F. Factors determining cellular mechanisms of resistance to antimitotic drugs. Drug Resist Updat 2000;3:1-4.
5. Dumontet C. Mechanisms of action and resistance to tubulin-binding agents. Expert Opin Investig Drugs 2000;9:779-88.
6. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of taxol resistance related to microtubules. Oncogene 2003;22:7280-95.
7. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
8. Childs S, Yeh RL, Hui D, Ling V. Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein. Cancer Res 1998;58:4160-7.
9. Lecureur V, Sun D, Hargrove P, et al. Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol 2000;57:24-35.
10. Hopper-Borge E, Chen ZS, Shchaveleva I, Belinsky MG, Kruh GD. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res 2004;64:4927-30.
11. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-27.
12. Kavallaris M, Kuo DY, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997;100:1282-93.
13. Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 1998;77:562-6.
14. Martello LA, Verdier-Pinard P, Shen HJ, et al. Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation. Cancer Res 2003;63:1207-13.
15. Giannakakou P, Sackett DL, Kang YK, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997;272:17118-25.
16. Giannakakou P, Gussio R, Nogales E, et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A 2000;97:2904-9.
17. He L, Yang C-PH, Horwitz SB. Mutations in beta-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines. Mol Cancer Ther 2001;1:3-10.
18. Gonzalez-Garay ML, Chang L, Blade K, Menick DR, Cabral F. A beta-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance. J Biol Chem 1999;274:23875-82.
19. Bhattacharya R, Cabral F. A ubiquitous beta-tubulin disrupts microtubule assembly and inhibits cell proliferation. Mol Biol Cell 2004;15: 3123-31.
20. Hari M, Yang H, Zeng C, Canizales M, Cabral F. Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton 2003;56:45-56.
21. Blade K, Menick DR, Cabral F. Overexpression of class I, II or IVb beta-tubulin isotypes in CHO cells is insufficient to confer resistance to paclitaxel. J Cell Sci 1999;112:2213-21.
22. Poruchynsky MS, Giannakakou P, Ward Y, et al. Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism. Biochem Pharmacol 2001;62:1469-80.
23. Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L, Sikic BI. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res 1996;56:1091-7.
24. Greenberger LM, Collins KI, Annable T, et al. alpha-(3,4-dimethyoxyphenyl)-3,4-dihydro-6,7-dimethoxy-alpha- [(4-methylphenyl)thiol-2(1H)-isoquinolineheptanenitrile (CL 329,753): a novel chemosensitizing agent for P-glycoprotein-mediated resistance with improved biological properties compared with verapamil and cyclosporine A. Oncol Res 1996;8:207-18.
25. Schibler MJ, Barlow SB, Cabral F. Elimination of permeability mutants from selections for drug resistance in mammalian cells. FASEB J 1989;3: 163-8.
26. Jaffrezou JP, Dumontet C, Derry WB, et al. Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncol Res 1995;7:517-27.
27. Loganzo F, Discafani CM, Annable T, et al. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res 2003;63:1838-45.
28. Loganzo F, Hari M, Annable T, et al. Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin. Mol Cancer Ther 2004;3:1319-27.
29. Verdier-Pinard P, Wang F, Martello L, Burd B, Orr GA, Horwitz SB. Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry. Biochemistry 2003;42:5349-57.
30. Best D, Warr PJ, Gull K. Influence of the composition of commercial sodium dodecyl sulfate preparations on the separation of alpha- and beta-tubulin during polyacrylamide gel electrophoresis. Anal Biochem 1981; 114:281-4.
31. Hari M, Wang Y, Veeraraghavan S, Cabral F. Mutations in alpha- and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine. Mol Cancer Ther 2003;2:597-605.
32. Minotti AM, Barlow SB, Cabral F. Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J Biol Chem 1991;266:3987-94.
33. Lowe J, Li H, Downing KH, Nogales E. Refined structure of alpha beta-tubulin at 3.5 Å resolution. J Mol Biol 2001; 313:1045-57.
34. Nogales E, Wolf SG, Downing KH. Structure of the alpha beta tubulin dimer by electron crystallography. Nature 1998;391:199-203.
35. Webster DR, Borisy GG. Microtubules are acetylated in domains that turn over slowly. J Cell Sci 1989;92:57-65.
36. Palazzo A, Ackerman B, Gundersen GG. Cell biology: tubulin acetylation and cell motility. Nature 2003;421:230.
37. Wang Y, Veeraraghavan S, Cabral F. Intra-allelic suppression of a mutation that stabilizes microtubules and confers resistance to colcemid. Biochemistry 2004;43:8965-73.
38. Cabral FR, Brady RC, Schibler MJ. A mechanism of cellular resistance to drugs that interfere with microtubule assembly. Ann N Y Acad Sci 1986;466:745-56.
39. Snyder JP, Nettles JH, Cornett B, Downing KH, Nogales E. The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density. Proc Natl Acad Sci U S A 2001;98:5312-6.
40. Rao S, Krauss NE, Heerding JM, et al. 3′-(p-azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin. J Biol Chem 1994;269:3132-4.
41. Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, Downing KH. The binding mode of epothilone A on alpha, beta-tubulin by electron crystallography. Science 2004;305:866-9.
42. Bode CJ, Gupta ML, Jr., Reiff EA, Suprenant KA, Georg GI, Himes RH. Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry 2002;41:3870-4.
43. Diaz JF, Menendez M, Andreu JM. Thermodynamics of ligand-induced assembly of tubulin. Biochemistry 1993;32:10067-77.
44. Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993;32:2747-55.
45. Kelley MJ, Li S, Harpole DH. Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer. J Natl Cancer Inst 2001;93:1886-8.